- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07895394
Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
Analysis of Vaccine-induced Immune Responses and Optimization of Protective Immunity Against Respiratory Syncytial Virus in Lung Transplant Recipients
The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
- Lung transplant recipients and immunocompetent adults who are willing to receive a respiratory syncytial virus (RSV) vaccine will be recruited at the study hospital.
- Participants will receive a single intramuscular dose of the RSV vaccine (RSVPreF3, Arexvy®)
- Participants will be contacted by telephone on Day 7 and at the Day 30 follow-up visit after vaccination to assess adverse events.
- Immunogenicity will be evaluated before vaccination and at 1 month and 12 months after vaccination, and safety will be monitored throughout the study period.
- Changes in immune responses from pre-vaccination levels will be compared between lung transplant recipients and immunocompetent adults.
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studiecontact
- Naam: Chan Mi Lee, M.D., PhD.
- Telefoonnummer: 82-2-2072-1473
- E-mail: heaven229@naver.com
Studie Contact Back-up
- Naam: Young Hoon Hwang, M.D.
- Telefoonnummer: 82-2-2072-2228
- E-mail: hyh0307@gmail.com
Studie Locaties
-
-
Jongno-Gu
-
Seoul, Jongno-Gu, Zuid -Korea, 03080
- Werving
- Seoul National University Hospital
-
Contact:
- Nam Joong Kim, M.D., PhD.
- Telefoonnummer: 82-2-2072-0835
- E-mail: njkmd@snu.ac.kr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria (for lung transplant recipient) :
- Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study
- Recipients of a lung transplant who are receiving immunosuppressive therapy to prevent allograft rejection.
Inclusion Criteria (for control) :
- Adults aged 60 years or older who voluntarily provide written informed consent to participate in the study.
- Individuals who do not have medical conditions associated with immunocompromise (e.g., malignancy, bone marrow transplantation, solid organ transplantation, HIV infection, or dialysis) and have not received ongoing chemotherapy, radiation therapy, immunosuppressive therapy, or immunomodulatory therapy within 6 months before vaccination.
Exclusion Criteria:
Participants will be excluded if they meet any of the following criteria
- Previous receipt of any RSV vaccine.
- RSV infection diagnosed within the past 12 months.
- History of a severe allergic reaction to any component of the RSV vaccine.
- Moderate or severe acute illness at the time of screening.
- Pregnancy, planned pregnancy, or breastfeeding.
- Any underlying medical condition for which intramuscular injection is contraindicated.
- Any other condition that, in the investigator's judgment, may make the participant unsuitable for evaluation of immune responses.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Lung transplant recipient
Lung transplant recipients aged ≥19 years receiving immunosuppressive therapy (n=60) |
One dose of RSVPreF3 (Arexvy®) vaccine |
|
Actieve vergelijker: Control
Immunocompetent adults aged ≥60 years (n=20) |
One dose of RSVPreF3 (Arexvy®) vaccine |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Humoral immune response (neutralizing antibody)
Tijdsspanne: 1 month after vaccination
|
Geometric mean fold rise (GMFR) in RSV-A neutralizing antibody titers from pre-vaccination to 1 month after vaccination, compared between lung transplant recipients and immunocompetent adults. |
1 month after vaccination
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Humoral immune response (neutralizing antibody)
Tijdsspanne: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean titers (GMTs) in RSV-A neutralizing antibody titers |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
Tijdsspanne: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean titers (GMTs) in RSV-B neutralizing antibody titers |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
Tijdsspanne: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSV-A neutralizing antibody titers from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
Tijdsspanne: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSV-B neutralizing antibody titers from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Tijdsspanne: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean concentrations (GMCs) in RSVPreF3-specific IgG |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Tijdsspanne: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean concentrations (GMCs) in pan-RSV-specific IgG |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Tijdsspanne: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSVPreF3-specific IgG from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Tijdsspanne: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in pan-RSV-specific IgG from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (serologic response rate)
Tijdsspanne: 1 month, 12 months after vaccination
|
Proportion of participants with a ≥4-fold increase in antibody levels from pre-vaccination levels |
1 month, 12 months after vaccination
|
|
Cell mediated immunity
Tijdsspanne: 1 month, 12 months after vaccination
|
Frequency of RSV F-specific CD4+ and CD8+ T cells following stimulation with RSV F peptide pools, measured by flow cytometry. |
1 month, 12 months after vaccination
|
|
Safety (solicited adverse events)
Tijdsspanne: 7 days, 30 days after vaccination
|
Proportion of participants experiencing solicited local and systemic adverse events following vaccination. |
7 days, 30 days after vaccination
|
|
Safety (unsolicited adverse events, serious adverse events)
Tijdsspanne: Up to 12 months after vaccination
|
Proportion of participants experiencing unsolicited adverse events or serious adverse events following vaccination. |
Up to 12 months after vaccination
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Nam Joong Kim, M.D., PhD., Seoul National University Hospital
Publicaties en nuttige links
Algemene publicaties
- Walsh EE, Perez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, Ramet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B; RENOIR Clinical Trial Group. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5.
- Tan CS, Anjan S, Ariza-Heredia EJ, Magana F, Minniear TD, Kaur D, Falck-Ytter Y, Baden L. IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal RSV Infections in Immunocompromised Patients. Clin Infect Dis. 2026 Aug 24;82(Suppl 3):i123-i128. doi: 10.1093/cid/ciag117.
- Mayer EF, Falsey AR, Wolfe CR, Herc E, Burns F, Kabbani D, Kumar D, Mannan A, She F, Lan L, McGrath S, Kapoor A, Priddy F. Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345. Clin Infect Dis. 2026 May 20;82(5):e1112-e1121. doi: 10.1093/cid/ciag108.
- Levy L, Yahav D, Benzimra M, Bezalel Y, Hoffman T, Shirin N, Sinai T, Jurkowicz M, Deri O, Matalon N, Saute M, Lustig Y, Nachum E, Peled M, Nemet I, Mandelboim M. Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains. Vaccines (Basel). 2025 Apr 11;13(4):398. doi: 10.3390/vaccines13040398.
- Ferguson M, Schwarz TF, Nunez SA, Rodriguez-Garcia J, Mital M, Zala C, Schmitt B, Toursarkissian N, Mazarro DO, Grosskopf J, Voors-Pette C, Mehta H, Hailemariam HA, de Heusch M, Salaun B, Damaso S, David MP, Descamps D, Hill J, Vandermeulen C, Hulstrom V; RSV OA=ADJ-018 Study Group. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to >/=60 Years of Age. Clin Infect Dis. 2024 Oct 15;79(4):1074-1084. doi: 10.1093/cid/ciae364.
- Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, Ortega-Sanchez IR, Broder KR, Talbot HK, Long SS, Havers FP, Melgar M. Use of Respiratory Syncytial Virus Vaccines in Adults Aged >/=60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702. doi: 10.15585/mmwr.mm7332e1.
- Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, Havers FP. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801. doi: 10.15585/mmwr.mm7229a4.
- Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrom V; AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
- Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, Fischetti CA, Shinde V. Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection. J Infect Dis. 2020 Sep 14;222(8):1298-1310. doi: 10.1093/infdis/jiaa361.
- Na SH, Jo HJ, Park JJ, Seo Y, Lee J, Bae J, Lee M, Lee CM, Kang CK, Choe PG, Park WB, Kim NJ. Comparison of clinical characteristics and outcomes in hospitalized adult patients infected with respiratory syncytial virus and influenza virus. Infect Dis (Lond). 2025 Feb;57(2):159-166. doi: 10.1080/23744235.2024.2402914. Epub 2024 Sep 16.
- de Zwart A, Riezebos-Brilman A, Lunter G, Vonk J, Glanville AR, Gottlieb J, Permpalung N, Kerstjens H, Alffenaar JW, Verschuuren E. Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies. Clin Infect Dis. 2022 Jul 6;74(12):2252-2260. doi: 10.1093/cid/ciab969.
- Havers FP, Whitaker M, Melgar M, Chatwani B, Chai SJ, Alden NB, Meek J, Openo KP, Ryan PA, Kim S, Lynfield R, Shaw YP, Barney G, Tesini BL, Sutton M, Talbot HK, Olsen KP, Patton ME; RSV-NET Surveillance Team. Characteristics and Outcomes Among Adults Aged >/=60 Years Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus - RSV-NET, 12 States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 6;72(40):1075-1082. doi: 10.15585/mmwr.mm7240a1.
- Tin Tin Htar M, Yerramalla MS, Moisi JC, Swerdlow DL. The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis. Epidemiol Infect. 2020 Feb 13;148:e48. doi: 10.1017/S0950268820000400.
- Solidoro P, Curtoni A, Minuto S, Shbaklo N, De Rosa FG, Bondi A, Sidoti F, Patrucco F, Zanotto E, Corcione S, Boffini M, Marro M, Costa C, Rinaldo RF. Impact of RSV Infection in Transplant and Immunocompromised Population: Incidence and Co-Infections: Retrospective Analysis of a Single Centre. J Clin Med. 2025 Jul 7;14(13):4803. doi: 10.3390/jcm14134803.
- Mahan LD, Points A, Mohanka MR, Bollineni S, Joerns J, Kaza V, La Hoz RM, Gao A, Zhang S, Torres F, Banga A. Characteristics and outcomes among lung transplant patients with respiratory syncytial virus infection. Transpl Infect Dis. 2021 Aug;23(4):e13661. doi: 10.1111/tid.13661. Epub 2021 Jun 22.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 2608-187-1775
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
We are not planning to share IPDs publically, but de-identified individual participant data for all outcome measures could be shared with other researchers under their request.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .